Taysha Gene Therapies (TSHA) Operating Margin: 2022-2025
Historic Operating Margin for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to 226,826.67%.
- Taysha Gene Therapies' Operating Margin rose 22827510.00% to 226,826.67% in Q3 2025 from the same period last year, while for Sep 2025 it was -1,622.40%, marking a year-over-year decrease of 73714.00%. This contributed to the annual value of -1,097.55% for FY2024, which is 62872.00% down from last year.
- Taysha Gene Therapies' Operating Margin amounted to 226,826.67% in Q3 2025, which was up 16,938.40% from -1,347.08% recorded in Q2 2025.
- Taysha Gene Therapies' 5-year Operating Margin high stood at 226,826.67% for Q3 2025, and its period low was -1,915.38% during Q2 2024.
- For the 3-year period, Taysha Gene Therapies' Operating Margin averaged around 19,760.44%, with its median value being -930.54% (2025).
- In the last 5 years, Taysha Gene Therapies' Operating Margin tumbled by 774,041bps in 2023 and then skyrocketed by 22,827,510bps in 2025.
- Quarterly analysis of 4 years shows Taysha Gene Therapies' Operating Margin stood at 4,135.33% in 2022, then slumped by 458,610bps to -450.78% in 2023, then crashed by 53,498bps to -985.76% in 2024, then spiked by 22,827,510bps to 226,826.67% in 2025.
- Its Operating Margin stands at 226,826.67% for Q3 2025, versus -1,347.08% for Q2 2025 and -930.54% for Q1 2025.